FFM
NGNE icon

Fairmount Funds Management’s Neurogene NGNE Stock Holding History

Fairmount Funds Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,637
Closed -$4.47M – 20
2020
Q3 		$4.47M Sell
18,637
-19,867
-52% -$4.81M 1.89% 15
2020
Q2 		$12.8M Sell
38,504
-2,000
-5% -$521K 5.7% 8
2020
Q1 		$9.22M Hold
40,504
– – 5.59% 9
2019
Q4 		$9.98M Buy
+40,504
New +$4.03M 6.05% 9

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fairmount Funds Management's NGNE Position: Q4 2020 in Review

Fairmount Funds Management sold out of Neurogene (NGNE) in Q4 2020, closing a stake of 18,637 shares — an estimated $4.47M sold.

Fairmount Funds Management first reported a position in NGNE in Q4 2019 and held it in 4 quarters. The position peaked at $12.8M in Q2 2020. 84 funds tracked by Wall St. Rank hold NGNE as of Q4 2020.

  • Fairmount Funds Management reported no remaining Neurogene position as of Q4 2020 after selling out during the quarter.
  • Fairmount Funds Management sold 18,637 Neurogene shares in Q4 2020, an estimated $4.47M.
  • Fairmount Funds Management first reported a position in Neurogene in Q4 2019 and held it in 4 quarters.
  • Fairmount Funds Management's Neurogene position peaked at $12.8M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Neurogene as of Q4 2020.

Based on Fairmount Funds Management's 13F filing for Q4 2020, filed 12 Feb 2021.